



**SOLVE  
ON.**

## **Incyte Recognized as an Exceptional Workplace by both *Science* Magazine and *Newsweek***

**WILMINGTON, Del. – October 27, 2022** – *Science* Magazine announced today that for the fifth consecutive year, Incyte has been named as a top five biopharma employer based on *Science*'s annual survey. Incyte ranked fourth on this year's list and was specifically recognized for being an innovative leader in the industry, being socially responsible and treating employees with respect.

The *Science* Magazine Top Employer achievement comes just weeks after Incyte was featured by *Newsweek* on its Most Loved Workplace® list for the second year in a row. Incyte moved up 16 spots to #61 among the top 100 companies recognized for employee happiness and satisfaction at work.

Incyte is proud to be recognized by *Science* and *Newsweek*. The company seeks to create an environment where innovation, inspiration, collaboration and respect are prioritized, and believes every employee plays a role in making a difference in the lives of patients. As Incyte looks to grow its talented team, the Company remains dedicated to creating an atmosphere where employees can grow and thrive to their full potential.

The complete *Science* Magazine Top Employers survey feature, along with individual company rankings, is available in the October 28, 2022 print issue of *Science* and online: <https://www.science.org/content/article/2022-s-top-employers-provide-safety-support-and-success-scientists>.

Additionally, the full *Newsweek* list of 2022 Most Loved Workplaces, featured in the magazine's October 14, 2022 print edition, is currently available online at <https://www.newsweek.com/rankings/americas-100-most-loved-workplaces-2022>.

### **About *Science* Magazine Top Employers**

The *Science* 2022 Top Employers Survey polled employees in biotechnology, biopharmaceutical, pharmaceutical and related industries to determine the 20 best employers as well as the employers' driving characteristics. The findings are based on more than 6,200 completed surveys from readers of *Science* and other survey invitees. Survey respondents came from North America (63%), Europe (15%), Asia/Pacific Rim (17%) and other locations (5%).

### **About *Newsweek* Top 100 Most Loved Workplaces®**

The Top 100 Most Loved Workplaces® are the result of a collaboration between *Newsweek* and the Best Practice Institute (BPI), a leadership development and benchmark research company. The results were determined after surveying more than 1.4 million employees from businesses with workforces varying in size from 50 to more than 10,000. The list recognizes companies that put respect, caring and appreciation for their employees at the center of their business model and, in doing so, have earned the loyalty and respect of the people who work for them.

To identify the top 100 companies for the *Newsweek* ranking, companies were evaluated and scored as follows: 35% of the initial score was based on employee survey responses; 25% was derived from analysis of external public ratings from sites such as Comparably, Careerbliss, Glassdoor, Indeed and Google; and 40% came from direct interviews with and written responses from company officials. *Newsweek* then conducted additional research into every company on the list, as well as the top runners up, to determine the final list of 100 companies and their ranking.

#### **About Best Practice Institute**

Best Practice Institute is an award-winning leadership and organization development center, benchmark research company, think tank and solutions provider. BPI is the certifying body for Most Loved Workplace® and conducted the original research to create the model and criteria for becoming a Most Loved Workplace®. BPI's research proves that Most Loved Workplaces® produce 3-4 times better customer service, employee performance, and retention than companies not loved by their employees.

#### **About Incyte**

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit [Incyte.com](http://Incyte.com) and follow [@Incyte](https://twitter.com/Incyte).

###

#### **Contact:**

#### **Media**

Catalina Loveman

+1 302 498 6171

[cloveman@incyte.com](mailto:cloveman@incyte.com)